Sanofi-Aventis' Menactra Post-Approval Commitments Should Include Long-Term Safety, Efficacy Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The quadravalent meningococcal conjugate vaccine displayed immunogenicity and safety similar to Menomune, an FDA Advisory Committee says. Sanofi-Aventis says that preliminary results from a three-year follow-up study suggest that Menactra patients have longer antibody persistence than Menomune.
You may also be interested in...
Sanofi’s Menactra Use Expanded To Children
Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.
Sanofi’s Menactra Use Expanded To Children
Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.
Sanofi-Aventis Eyes Expanded Menactra Indication Following Initial Approval
FDA approves the meningococcal conjugate vaccine for patients 11-55 years old; Sanofi-Aventis will submit a sBLA for use in children ages 2-11 by February. The company is currently studying the vaccine in patients under age 2 and will initiate a study evaluating Menactra in subjects over age 55 years by January 2006.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: